Diabetes Mellitus Clinical Trial
Official title:
CSP #705D - Screening for Diabetes Mellitus in Veterans
Population-based screening for diabetes mellitus in non-pregnant adults remains
controversial. For a screening strategy to be successful, patients identified by
surveillance will have to have better outcomes than if they had been diagnosed at a later,
more symptomatic phase of disease. However, little is known about the fate of patients
diagnosed with diabetes by screening. Additionally, while about half of the cases of
diabetes among the general population at any given time are undiagnosed, the prevalence of
undiagnosed diabetes among veterans is unknown. The annual incidence of diabetes among
veterans is also unknown.
Assessing risk factors prior to blood testing will improve the specificity, with little cost
in sensitivity, of screening for diabetes in a medical center setting. The target population
which optimizes the potential value of diabetes screening is patients with at least 1 of the
above 3 risk factors for diabetes (obesity, hypertension, family history). Hypertension is
strongly associated with unrecognized diabetes in veterans. VA and other health care
providers considering whether to perform systematic screening for diabetes should use known
risk factors to identify an appropriate target population for screening.
Primary Objectives: To measure the prevalence of undiagnosed Diabetes Mellitus (DM) and the
annual incidence of new cases of DM among veterans between the ages of 45 and 64 and to
compare the health-related quality of life (HRQoL) of veterans with undiagnosed DM to those
without DM but who are at comparable risk for DM, both at baseline and over three years of
follow-up.
Secondary Objectives: To describe the clinical state of veterans with diabetes newly
diagnosed by screening and to describe the process of usual care for veterans with diabetes
newly diagnosed by screening.
Primary Outcomes: The primary outcomes are: 1) prevalence of undiagnosed
non-insulin-dependent diabetes mellitus (NIDDM); 2) HRQoL as measured by SF-36; 3) glycemic
control as measured by HbA1C; and 4) calculation of the 3-year direct utilization-related
cost, from the perspective of the VA, associated with early diagnosis of DM, and comparison
of this to the 3-year direct utilization-related cost for veterans who are screened for
diabetes but do not have diabetes.
Intervention: N/A
Study Abstract: Population-based screening for diabetes mellitus in non-pregnant adults
remains controversial. For a screening strategy to be successful, patients identified by
surveillance will have to have better outcomes than if they had been diagnosed at a later,
more symptomatic phase of disease. However, little is known about the fate of patients
diagnosed with diabetes by screening. Additionally, while about half of the cases of
diabetes among the general population at any given time are undiagnosed, the prevalence of
undiagnosed diabetes among veterans is unknown. The annual incidence of diabetes among
veterans is also unknown.
A mail-out survey for this study was completed with 10,350 surveys mailed and 4,500 surveys
returned (43%). Enrollment concluded 7/31/99 with 1,253 new subjects enrolled. Follow-up of
the enrolled subjects is ongoing. Some descriptive analyses of the data revealed the
prevalence of undiagnosed diabetes was 4.5%. Factors associated with unrecognized diabetes
were the diagnosis of hypertension and history of a parent or sibling with diabetes. Having
a primary care provider did not raise or lower the risk for unrecognized diabetes. Based on
the new diagnosis, most patients found to have diabetes required a change in treatment
either of their blood sugar or comorbid hypertension or hyperlipidemia in order to achieve
targets recommended in published treatment guidelines. Patients reporting a primary care
provider were no less likely to require a change in treatment.
Conclusions: If diabetes screening is an effective intervention, opportunistic screening for
diabetes may be the preferred method for screening, as there is substantial potential for
case-finding in a medical center outpatient setting. A majority of patients with diabetes
diagnosed at opportunistic screening will require a change in treatment of blood sugar,
blood pressure, or lipids to receive optimal care.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |